Airway eosinophilia is typical of asthma, and many controller treatments target eosinophilic disease. Asthma is clinically heterogeneous, however, and a subgroup of asthmatics do not have airway eosinophilia. The size of this subgroup is uncertain because prior studies have not examined repeated measures of sputum cytology to determine when asthmatics have intermittent versus persistent sputum eosinophila and when they are persistently non-eosinophilic.
INTRODUCTION
Asthma is a common disease affecting people across the lifespan; it costs US society $56 billion annually (1) . Airway eosinophilia is well-described in asthma (2) (3) (4) , and currently available anti-inflammatory treatments for asthma almost exclusively target eosinophilic airway inflammation (5, 6) . Many asthmatics respond sub-optimally to currently available eosinophil-directed treatments, however, most likely because they do not have airway eosinophilia (7) (8) (9) (10) (11) (12) (13) .
Increased attention is focusing on the clinical heterogeneity of asthma and the argument that failure to recognize and discover the underlying mechanisms of different asthma subtypes is a major limitation to progress (14) . Continued uncertainly about the prevalence of eosinophilic versus non-eosinophilic subtypes of asthma and about the relationship between airway eosinophilia and treatment responses relates to limitations in previous studies of these issues. The principal limitation of these studies has been that they have usually lacked repeated measures of airway eosinophils, and they have not assessed treatment responses in subjects whose eosinophil phenotype has been categorized by repeated eosinophil measures. The clinical trials supported by National Heart and Lung Institute's Asthma Clinical Research Network (ACRN) provide a valuable resource to address the limitations of prior studies. For example, ACRN studies have frequently included measures of sputum cytology, often measured repeatedly, and done according to standardized protocols and quality control (15) .
ACRN studies have also included assessment of treatment responses to periods of combined therapy with inhaled and oral corticosteroids, and leukotriene receptor antagonists. Pooled data from asthmatic subjects enrolled in these ACRN studies allowed us to generate robust estimates for the prevalence of eosinophilic phenotypes of asthma and to evaluate the relationship between these phenotypes and treatment responses. Some of the results of these study have been previously reported in the form of an oral presentation at the ATS 2011 International meeting.
METHODS

Subjects
Data were derived from 995 asthmatic subjects enrolled in nine clinical trials conducted by the ACRN that included at least one sputum induction as part of the study protocol (aggregated NCT00000577) (Table 1s in supplementary appendix) (8, 9, (16) (17) (18) (19) (20) (21) . All subjects were between the ages of 12 and 70 years, met the criteria for persistent asthma as defined by the NAEPP Guidelines for the Diagnosis and Management of Asthma(22), and were current non-smokers with a lifetime history of smoking no greater than 10 pack-years. In addition, all subjects had either a positive PC 20 methacholine of ≤16mg/mL when on ICS or ≤8 mg/ml when not on inhaled corticosteroids (ICS); or a post-bronchodilator increase in FEV 1 of ≥12%. Sputum induction data and corresponding clinical data were only included when ICS use or non-use was known and standardized as part of the study protocol at the time of the sputum induction. Of the 995 subjects, 645 had received their baseline sputum assessment after a standardized run-in on low-dose ICS (ICS+), and 350 subjects had not been treated with ICS for at least 2 weeks at the time of baseline sputum assessment (ICS-)( Figure   1s in the supplementary appendix). For repeated measure subgroups (n=324), 167 F o r R e v i e w O n l y ICS+ asthmatics had received baseline sputum assessment after at least 4 weeks of standardized low-dose ICS, while 157 ICS-asthmatics had not used ICS for at least 8 weeks prior to baseline sputum assessment ( Figure 1s ). Studies had been reviewed and approved by institutional review boards at all participating ACRN centers, and all subjects provided informed consent.
Sputum Induction
Sputum was collected using methods validated for consistency and quality control, as previously described (15, 23, 24) . Briefly, subjects had spirometry performed before and 10 minutes after pretreatment with 360ug of albuterol to ensure that post-bronchodilator FEV1>60% predicted. A 12-minute sputum induction was then performed, and cell differentials (eosinophils, neutrophils, macrophages, epithelial cells, and lymphocytes) were calculated as the percentage of cells in the whole sputum expectorate. The mean ± SD % of squamous cells was 31.6 ± 19.0% in the ICS-group and 35.8 ± 19.4% in the ICS+ subgroup. The other cell types in the sputum were calculated as the percentage of non-squamous cells.
The presence or absence of eosinophilic inflammation was determined using a 2% cutoff based on published reference values for eosinophils in induced sputum from healthy subjects (25, 26) ; subjects with ≥2% sputum eosinophils were classified as having sputum eosinophilia, and subjects with <2% sputum eosinophils were classified as being non-eosinophilic. Continuous variables were presented within tables as means and standard deviations, when normally distributed, and medians and interquartile ranges, when not normally distributed. Categorical data were reported using frequencies and percentages. Preliminary analyses revealed three groups of eosinophilic phenotypes when subjects were evaluated using repeated measures: persistently eosinophilic, intermittently eosinophilic and persistently non-eosinophilic. Comparisons of these subgroups were evaluated using ordinal logistic regression to assess for trends.
Post-hoc exploratory hierarchical cluster analysis was performed in the subgroup of asthmatics who were persistently non-eosinophilic and who had not been treated with inhaled corticosteroids. Continuous and binary variables were centered and standardized; Ward's minimum variance method was used to establish clusters using fifteen variables which were available for all subjects. At each step, Ward's method combines clusters by merging the pair of clusters that minimizes the sum of squared deviations from the cluster mean, across all clusters.
The sensitivity and specificity of peripheral blood eosinophils and of nitric oxide levels in exhaled breath as biomarkers of sputum eosinophilia were calculated using data from all subjects who had not been treated with inhaled corticosteroids and who had either test done on the same day as a sputum collection; all paired measures available for each subject were included. A receiver operating characteristic (ROC) curve analysis F o r R e v i e w O n l y was used to both select cutoff values for peripheral blood eosinophils and fractional exhaled nitric oxide (FE NO ) that maximized sensitivity and specificity and to evaluate the sensitivity and specificity of these biomarkers using usual clinical cutoffs.
RESULTS
Cross-sectional analyses of sputum eosinophils and neutrophils in initial induced sputum samples.
Of the 995 asthmatics with induced sputum data available, 645 were being treated with an inhaled corticosteroid (ICS+) and 350 were not (ICS-). Both groups had disease severity characteristic of mild-to-moderate asthma as shown in Table 1 . In analyses of single induced sputum samples from these subjects, we found that sputum eosinophilia (≥2% eosinophils) occurs in a minority of both steroid-treated and untreated asthmatic subjects. In the ICS-subgroup, the distribution of sputum eosinophils was highly skewed ( Figure 1A ), with 64% of the subjects having fewer than 2% eosinophils. In the ICS+ subgroup, the distribution of sputum eosinophils was even more highly skewed with 83% of the subjects having fewer than 2% eosinophils ( Figure 1B ).
To determine if sputum eosinophilia is influenced by degree of asthma control, we analyzed induced sputum cytology in a subset of 486 subjects who had assessment of asthma control after receiving standardized treatment with low-dose ICS for 4-6 weeks as part of ACRN treatment protocols. Asthma control was assessed using FEV 1 , daytime symptoms, short-acting beta-agonist (SABA) use, and nocturnal awakenings.
We found that 26% of the subjects who achieved good asthma control had sputum eosinophilia compared to 15% of subjects who did not achieve good control (p=0.004) ( Figure 1C) . Thus, the majority of subjects who did not achieve good asthma control did not have sputum eosinophilia. for sputum eosinophilia, but the sensitivity of both tests was poor (34% and 49%, respectively). Using receiver operating characteristics, the highest achievable combination of sensitivity and specificity for peripheral blood eosinophil count was reached at a derived threshold of 220/uL, which yielded 72% sensitivity and 69% specificity ( Figure 2 ). For FE NO , a value of 20ppb discriminated those with sputum eosinophilia from those without with a sensitivity of 64% and specificity of 73%. We tested a combined metric using FE NO and peripheral blood eosinophils to evaluate whether these two tests would improve the ability to detect sputum eosinophilia; no improvements in sensitivity and specificity were seen using the combined metric (data not shown).
Neutrophilic subtypes of asthma have been proposed and described (27-29); we therefore also analyzed sputum neutrophils in the ACRN dataset. We found that However, when the definition of sputum eosinophilia included eosinophilia occurring on any one of the repeated sputum analyses, the percentage of subjects who had eosinophilic asthma increased from 36% to 53% in the ICS-subgroup and from 19% to 28% in the ICS+ subgroup ( Figure 4 ). This analysis also revealed that, among asthmatics in the ICS-subgroup, 22% of subjects had sputum eosinophilia on every occasion (persistent eosinophilia), 31% had eosinophilia on at least one occasion (intermittent eosinophilia), and 47% had <2% sputum eosinophils on every occasion (persistently non-eosinophilic); the corresponding values for the ICS+ subgroup were 7%, 20% and 72%, respectively. The distribution of eosinophilic asthma phenotypes across the age spectrum is shown in Table 2 in the supplementary appendix. In addition, the intra-class correlation coefficient and the within subject variability for the sputum cell counts is provided in Table 3 of the supplementary appendix.
To determine whether clinical characteristics differed among the three eosinophil phenotypes, we restricted our analyses to the 157 ICS-subjects with repeated measures, reasoning that single measures or steroid treatment could result in misclassification of eosinophil subtypes and confound our analyses. The eosinophilic phenotypes tended to be younger than the patients with persistently non-eosinophilic disease, although the proportions of subjects whose asthma had started in childhood were similar in all three subgroups (Table 2) . Interestingly, the persistently eosinophilic subgroup were much more likely than the non-eosinophilic subgroup to be of normal body weight ( Figure 5 ). In fact, BMI was normal in 73% of the persistently eosinophilic subgroup compared to only 45% of the non-eosinophilic subgroup and 32% of the American population-at-large (30). Although average FEV 1 values were not significantly different among subgroups (Table 2) , the percentage of subjects whose FEV 1 was <80% predicted was higher in the persistently eosinophilic subgroup ( Figure 5 ). In addition, bronchial hyperresponsiveness differed among subgroups ( percentage of subjects with severe bronchial hyperresponsiveness was higher in the persistently eosinophilic subgroup ( Figure 5 ). Notably, atopy was not confined to the eosinophilic phenotypes; most of the persistently non-eosinophilic subjects were also atopic, as evidenced by their IgE and aeroallergen sensitization data (Table 2 and Figure 5 ). Finally, sputum neutrophilia was uncommon in all groups, although it did occur in 21% of the persistently non-eosinophilic subgroup ( Figure 5 ).
To determine whether responses to asthma treatment differed among the three eosinophil phenotypes, we studied a subset of the ICS-subgroup (n=77) who had (Table 3) . One cluster comprised 42% of the 157 subjects and was characterized by younger age, female gender, lean body mass, well-preserved FEV 1 , and moderate-to-severe bronchial hyperresponsiveness. It resembles a cluster identified previously by others (31). Another cluster comprised 22% of the subjects and was characterized by older age, female gender, later onset asthma, high body mass index, low lung function, high sputum neutrophils, low IgE levels, and infrequent skin test reactivity to aeroallergens. The grouping of older heavier females with asthma of late onset has been described previously (31, 32). A third cluster comprised 36% of the subjects and was characterized by younger age, lean body mass, male gender, low FEV 1 , childhood onset asthma, and sensitivity to fungal aeroallergens (especially to alternaria). Interestingly, a previous study has described two sub-phenotypes of childhood asthma based on the presence or absence of alternaria skin test reactivity at age 6 (33) , and a characteristic of alternaria positive children was their high rate of asthma persistence after age 11.
DISCUSSION
Previous studies have called attention to heterogeneity in eosinophil phenotypes among asthmatics (7-13), but estimates for the prevalence of non-eosinophilic asthma in these prior studies were generated from single sputum samples. The importance and novelty of our paper is that we show that sputum eosinophilia is persistently absent in a large subgroup of mild/moderate asthma when sputum is analyzed repeatedly over time.
Subjects whose asthma was persistently non-eosinophilic had a very poor response to a period of intense combined treatment with asthma controller treatments, despite Among asthmatics with eosinophilia, some had it persistently and others had it intermittently. The clinical characteristics of eosinophilic asthma are most evident in the persistently eosinophilic subtype. Here we found a relatively homogeneous asthma phenotype characterized by normal body weight and greater bronchial hyperresponsiveness. Our data reporting the association of normal BMI with persistent eosinophilic asthma are novel, and a relative paucity of eosinophils in the airway of overweight or obese asthmatics may contribute to the relative glucocorticoid insensitivity observed in obese asthmatics (34) (35) (36) . Our findings also support the emerging concept that eosinophils play a role in metabolic homeostasis and prevention of obesity (37) .
Specifically, studies in mice show that eosinophils in white adipose tissue secrete T helper type 2 cytokines to induce alternative activation of macrophages, promote glucose homeostasis, and prevent obesity.
The intermittently eosinophilic subgroup was larger than the persistently eosinophilic subgroup and was characterized by lower average eosinophil percentages which often fell below the 2% cutoff for eosinophilia in repeated sputum analyses. Importantly, the treatment responses of intermittently eosinophilc asthma mirrored those of persistently eosinophilic asthma. Thus, intermittently eosinophilic asthma can be considered a less The advantage of categorizing intermittent and persistent eosinophil subtypes separately is that this categorization emphasizes that repeated measures of sputum eosinophils are necessary to properly identify eosinophilic asthma. In this regard, it is notable that peripheral blood eosinophils and FE NO cannot be relied upon to identify eosinophilic asthma phenotypes, because both of these tests were not sufficiently sensitive as biomarkers of sputum eosinophilia.
Persistently non-eosinophilic asthma comprised approximately half of asthmatics with mild-to-moderate disease in our study. The median values for sputum eosinophils in this subgroup were consistently closer to 0% than to the 2% cutoff on each of the repeated measure time-points. This provides confidence that these subjects indeed were noneosinophilic and were not a subgroup falling just below the 2% cutoff and thereby possibly explained by measurement variability. We considered the possibility that the low sputum eosinophil percentage could reflect good asthma control in the subjects studied and that estimates could be much higher in patients with less optimal disease control. In analyses to address this possibility, we surprisingly found that only 15% of subjects who did not achieve good control with ICS treatment had sputum eosinophilia; this compared to 26% of subjects with sputum eosinophilia among asthmatics who did achieve good asthma control with ICS treatment. We interpret this apparent discrepancy as revealing how the poor asthma control subgroup is enriched in non-eosinophilic asthmatics (because steroids do not control asthma in patients with this disease subtype). (84) 4 (13) 1 (3) 12 (22) 38 (70) 2 (4) 2 (4) 9 (12) 52 (71) 6 (8) 6 ( and ICS+ (D) asthma subgroups. The graphs reveal three subgroups of asthmatics, those with persistently eosinophilic asthma whose sputum eosinophil % is ≥2 on every occasion it was measured, those with intermittently eosinophilic asthma whose sputum eosinophil % is >2% on at least one occasion but can be less than 2% on some 
Sputum Induction
Sputum was collected using methods validated for consistency and quality control, as previously described (15, 23, 24) . Briefly, subjects had spirometry performed before and 10 minutes after pretreatment with 360ug of albuterol to ensure that post-bronchodilator FEV1>60% predicted. A 12-minute sputum induction was then performed, and cell differentials (eosinophils, neutrophils, macrophages, epithelial cells, and lymphocytes) were calculated as the percentage of cells in the whole sputum expectorate. In terms of the sputum cell readings, the sputum cytologists in the ACRN all underwent training at UCSF in 2-3 day workshops that also included training for other study personnel in sputum induction and sputum processing. The UCSF center provided a sputum core resource for centralized slide reading with the number of over-reads ranging from 20% to 100% of slides, depending on the study. For the center reads the cell reader was certified by the senior sputum cytologist at UCSF with ongoing monitoring of the concordance of center read vs. over-read. For the purposes of the data analysis presented here, the default was to use over-read data and to only use center read data when the over-read was not available. Of the sputum samples analyzed from 995 asthmatics, over-reads were used from 61% of the subjects and center reads from the remaining 39%. Table 2s : Intra-class correlation coefficient (ICC) and within subject standard deviation (SD) for sputum cell percentages. 
